Psychedelic Drugs Market – Global Industry Analysis and Forecast (2022-2029)

Psychedelic Drugs Market size was valued at US$ 3.20 Bn in 2021 and the total revenue is expected to grow at 15.10% through 2022 to 2029, reaching nearly US$ 9.85 Bn.

Psychedelic Drugs Market Overview:

Psychedelics are a group of hallucinogenic substances whose main function is to cause non-ordinary states of consciousness (sometimes known as "trips") by blocking the serotonin 2A receptor. This results in unique psychological, visual, and auditory changes, as well as a significantly changed state of consciousness in many people. Global Psychedelic Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

Psychedelic Drugs Market Dynamics:

Sensory impressions, energy levels, cognitive functions, and spiritual experiences are all improved or altered by psychedelic drugs. The three forms of psychedelic drugs are dissociative drugs (such as phencyclidine), empathogens, and serotonergic drugs (such as lysergic acid diethylamide). These drugs are used to treat the major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction, among other conditions. Due to the obvious advent of new psychedelic substances in recent years, the market for psychedelic drugs has seen substantial expansion. Furthermore, because psychedelic medications have repeatedly demonstrated their high rates of effectiveness in the treatment of nicotine addiction, alcohol addiction, and anxiety-related terminal illness, market growth is being driven by an increase in acceptance of the medications for treating depression. Additionally, new product launches by the top market players for market expansion are further estimated to lift the growth of the psychedelic drug market. For instance- Janssen Pharmaceuticals, Inc. gained FDA approval for its Spravato nasal spray to treat suicidal persons in August 2021. According to the research, around 11–12% of Americans suffer from serious depressive disorder, which can lead to suicide. As a result of this approval, these patients received great therapy, and the corporation was able to collect more income.

Psychedelic Drugs Market Segment Analysis:

The Gamma-hydroxybutyric acid segment is anticipated to adhere to the growth of the Psychedelic Drugs Market. In 2021, the gamma-hydroxybutyric acid segment will be the most popular, as Xyrem from Jazz Pharmaceutical is one of the oldest psychedelic medications on the market, with a large proportion of the market and belongs to the drug class. It's a Schedule III regulated substance, which means it needs to be prescribed and closely monitored by a physician. GHB in its prescription version is used to treat excessive daytime sleepiness. Gamma-hydroxybutyric acid also been used to treat alcoholism and drug withdrawal in few patients. GHB is used in the medical treatment of narcolepsy and, less commonly, alcoholism, however, its efficacy in comparison to other pharmacotherapies for alcoholism is yet unknown. It is occasionally used off-label to treat fibromyalgia. The active element of the pharmaceutical drug sodium oxybate is GHB (Xyrem). The United States Food and Drug Administration has approved sodium oxybate for the treatment of cataplexy and excessive daytime sleepiness (EDS) in people with narcolepsy. The narcolepsy segment is supplementing the growth of the Psychedelic Drugs Market. The narcolepsy section is expected to dominate in 2021, thanks to Jazz Pharmaceutical's Xyrem, which is used to treat the condition and is the market's largest stakeholder. Narcolepsy is a chronic sleep disorder characterised by daytime tiredness and sleep episodes. People with narcolepsy find it difficult to stay awake for long periods of time in any situation. Narcolepsy can create a slew of issues in your day-to-day existence. Despite the fact that narcolepsy is not a lethal disease, it can lead to accidents, injuries, and even life-threatening scenarios. People with narcolepsy may struggle to keep employment, do well in school, and maintain relationships due to attacks of severe daytime sleepiness.

Psychedelic Drugs Market Regional Insights:

North America is dominating the growth of the market in the forecast period owing to the increased prevalence of depression and mental diseases, regulatory reforms, advancements about psychedelics in the region. Further, shifting perspectives, less severe side effects associated with the medicaments, cost-effectiveness is projected to drive the growth of the market. the psychedelic pharmaceuticals industry is predicted to grow due to high demand in North America. However, the market faces some challenges, such as the uncertainty surrounding FDA approval, the early stage of the psychedelics industry's lifecycle, the stigma associated with psychedelic drug use, and so on. The objective of the report is to present a comprehensive analysis of the Psychedelic Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Psychedelic Drugs Market dynamics, structure by analyzing the market segments and project the Psychedelic Drugs Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Psychedelic Drugs Market make the report investor’s guide.

Psychedelic Drugs Market Scope: Inquire before buying

Global Psychedelic Drugs Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 3.20 Bn.
Forecast Period 2022 to 2029 CAGR: 15.10% Market Size in 2029: US $ 9.85 Bn.
Segments Covered: by Type • Lysergic Acid Diethylamide (LSD) • 3,4-MethylEnedioxyMethamphetamine (Ecstasy) • Phencyclidine • Gamma Hydroxybutyric Acid (GHB) • Etamine • Ayahuasca • Salvia • Psilocybin • Others
by Patient • Major Depressive Disorder • Resistant depression • Panic disorder • Post-traumatic stress disorder • Opiate Addiction • Narcolepsy • Others
by End-Use • Hospitals • Homecare • Specialty Clinics • Others

Psychedelic Drugs Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Psychedelic Drugs Market Key Players

Janssen Pharmaceuticals, • Hikma Pharmaceuticals PLC • COMPASS • Verrian • Pfizer Inc. • F. Hoffmann-La Roche Ltd. • Jazz Pharmaceuticals Inc. • PharmaTher Inc. • Avadel • Celon Pharma S.A. • NeuroRx, Inc. • usonainstitute.org • Celon Pharma S.A. • Red Light Holland • Neonmind Biosciences • Novamind • MindMed • Numinus • Entheon Biomedical

Frequently Asked Questions:

1. Which region has the largest share in Global Psychedelic Drugs Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Psychedelic Drugs Market? Ans: The Global Psychedelic Drugs Market is expected to grow at a CAGR of 15.10% during forecast period 2022-2029. 3. What is scope of the Global Psychedelic Drugs market report? Ans: Global Psychedelic Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Psychedelic Drugs market? Ans: The important key players in the Global Psychedelic Drugs Market are – , Janssen Pharmaceuticals,, Hikma Pharmaceuticals PLC, COMPASS, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd., Jazz Pharmaceuticals Inc., PharmaTher Inc., Avadel, Celon Pharma S.A., NeuroRx, Inc., usonainstitute.org, Celon Pharma S.A., Red Light Holland, Neonmind Biosciences, Novamind, MindMed, Numinus, and Entheon Biomedical 5. What is the study period of this market? Ans: The Global Psychedelic Drugs Market is studied from 2021 to 2029.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Patient 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Patient 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Patient 2.3.2. Primary Research 2.3.2.1. Data from Primary Patient 2.3.2.2. Breakdown of Primary Patient 3. Executive Summary: Psychedelic Drugs Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Psychedelic Drugs Market 3.4. Geographical Snapshot of the Psychedelic Drugs Market, By Manufacturer share 4. Psychedelic Drugs Market Overview, 2021-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Psychedelic Drugs Market 5. Supply Side and Demand Side Indicators 6. Psychedelic Drugs Market Analysis and Forecast, 2021-2029 6.1. Psychedelic Drugs Market Size & Y-o-Y Growth Analysis. 7. Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 7.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 7.1.1. Lysergic Acid Diethylamide (LSD) 7.1.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy) 7.1.3. Phencyclidine 7.1.4. Gamma Hydroxybutyric Acid (GHB) 7.1.5. Etamine 7.1.6. Ayahuasca 7.1.7. Salvia 7.1.8. Psilocybin 7.1.9. Others 7.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 7.2.1. Major Depressive Disorder 7.2.2. Resistant depression 7.2.3. Panic disorder 7.2.4. Post-traumatic stress disorder 7.2.5. Opiate Addiction 7.2.6. Narcolepsy 7.2.7. Others 7.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 7.3.1. Hospitals 7.3.2. Homecare 7.3.3. Specialty Clinics 7.3.4. Others 8. Psychedelic Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 9.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 9.1.1. Lysergic Acid Diethylamide (LSD) 9.1.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy) 9.1.3. Phencyclidine 9.1.4. Gamma Hydroxybutyric Acid (GHB) 9.1.5. Etamine 9.1.6. Ayahuasca 9.1.7. Salvia 9.1.8. Psilocybin 9.1.9. Others 9.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 9.2.1. Major Depressive Disorder 9.2.2. Resistant depression 9.2.3. Panic disorder 9.2.4. Post-traumatic stress disorder 9.2.5. Opiate Addiction 9.2.6. Narcolepsy 9.2.7. Others 9.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 9.3.1. Hospitals 9.3.2. Homecare 9.3.3. Specialty Clinics 9.3.4. Others 10. North America Psychedelic Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 11.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 11.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 11.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 12. Canada Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 12.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 12.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 12.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 13. Mexico Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 13.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 13.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 13.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 14. Europe Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 14.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 14.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 14.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 15. Europe Psychedelic Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 16.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 16.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 16.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 17. France Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 17.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 17.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 17.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 18. Germany Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 18.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 18.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 18.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 19. Italy Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 19.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 19.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 19.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 20. Spain Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 20.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 20.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 20.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 21. Sweden Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 21.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 21.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 21.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 22. CIS Countries Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 22.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 22.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 22.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 23. Rest of Europe Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 23.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 23.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 23.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 24. Asia Pacific Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 24.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 24.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 24.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 25. Asia Pacific Psychedelic Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 26.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 26.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 26.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 27. India Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 27.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 27.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 27.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 28. Japan Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 28.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 28.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 28.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 29. South Korea Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 29.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 29.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 29.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 30. Australia Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 30.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 30.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 30.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 31. ASEAN Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 31.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 31.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 31.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 32. Rest of Asia Pacific Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 32.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 32.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 32.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 33. Middle East Africa Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 33.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 33.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 33.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 34. Middle East Africa Psychedelic Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 35.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 35.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 35.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 36. GCC Countries Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 36.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 36.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 36.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 37. Egypt Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 37.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 37.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 37.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 38. Nigeria Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 38.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 38.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 38.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 39. Rest of ME&A Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 39.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 39.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 39.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 40. South America Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 40.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 40.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 40.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 41. South America Psychedelic Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 42.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 42.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 42.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 43. Argentina Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 43.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 43.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 43.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 44. Rest of South America Psychedelic Drugs Market Analysis and Forecasts, 2021-2029 44.1. Market Size (Value) Estimates & Forecast By Type, 2021-2029 44.2. Market Size (Value) Estimates & Forecast By Patient, 2021-2029 44.3. Market Size (Value) Estimates & Forecast By End-Use, 2021-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Psychedelic Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Merck & Co., Inc. 45.3.1.1. Financial Overview 45.3.1.2. Geographic Footprint 45.3.1.3. Grade Portfolio 45.3.1.4. Business Strategy 45.3.1.5. Recent Developments 45.3.2. Janssen Pharmaceuticals, 45.3.3. Hikma Pharmaceuticals PLC 45.3.4. COMPASS 45.3.5. Verrian 45.3.6. Pfizer Inc. 45.3.7. F. Hoffmann-La Roche Ltd. 45.3.8. Jazz Pharmaceuticals Inc. 45.3.9. PharmaTher Inc. 45.3.10. Avadel 45.3.11. Celon Pharma S.A. 45.3.12. NeuroRx, Inc. 45.3.13. usonainstitute.org 45.3.14. Celon Pharma S.A. 45.3.15. Red Light Holland 45.3.16. Neonmind Biosciences 45.3.17. Novamind 45.3.18. MindMed 45.3.19. Numinus 45.3.20. Entheon Biomedical 46.Primary Key Insights
  • INQUIRE BEFORE BUYING